Category Archives: Inside BIO Industry Analysis

Therapeutic Discovery Project Awards Provide Much Needed R&D Support

This morning, U.S. Treasury Secretary Timothy Geithner and HHS Secretary Kathleen Sebelius announced the awardees of the Therapeutic Discovery Project (TDP). We are running a few analytics on the recipient list and posting them here, along with links to relevant articles/blogs. Here is a primer: 5600 projects were submitted by ~3000 companies The maximum amount a project received was $244,479 78% of projects received the maximum amount Average project award was $217,108 72% of the Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

State of the Industry – From BIO Investor Forum 2010

Here is our slide deck from the 9th annual BIO Investor Forum in San Francisco: BIO Investor Forum 2010 final   From the media and blogosphere: Bloomberg in vivo blog Medical Technology Stock Letter

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

IPO update: 28 IPOs, 24 on Deck

The number of IPOs slowed during the summer, but the queue has been filling nicely.  Fifteen more biotechs have filed to go public in the last month and a half, bringing the total to 24 globally. The two US IPOs this summer were from NuPATH and Trius. Again, we saw a reduction in the amount planned vs actually raised for these IPOs. On average, US biotechs have raised an amount 28% below what is first Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , ,

1Q Cash Spending – Small Biotechs Still Spending Less

A comparison of cash spent on operations in the 1st quarter of 2010 vs the 1st quarters of 2009 and 2008 for small public biotechs shows a slowing in the precipitous drop seen over the last 2 years. However, the average small biotech is still spending less cash vs. 2008. When compared to 1Q08, the median cash flow from operations (CFO) in 1Q10 is down -40%. From 1Q09, median CFO is down -15%. See chart Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , ,

Biotech Sector Performance Update 1H 2010

In my last update back in April, the broadest Biotech index (the 125 company Nasdaq Biotech Index, NBI) was up 11% for the year and ahead of just about every major sector. One quarter later things look a little different. The NBI is now down 5% and trailing 4 of the 10 S&P sectors (chart 1): However, the spotlight continues to shine on the AMEX Biotech Index (BTK). The BTK is up 8.6% for the Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , ,